MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.6302
+0.0002
+0.03%
Opening 15:33 10/03 EDT
OPEN
0.6158
PREV CLOSE
0.6300
HIGH
0.6396
LOW
0.5800
VOLUME
60.73K
TURNOVER
24.23K
52 WEEK HIGH
1.829
52 WEEK LOW
0.5040
MARKET CAP
46.92M
P/E (TTM)
-1.7506
1D
5D
1M
3M
1Y
5Y
BRIEF-Akari Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Pipeline Progress
BRIEF-Akari Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Pipeline Progress
Reuters · 6d ago
Akari Therapeutics GAAP EPS of $0.00
Akari Therapeutics press release (<span class="tick...
Seekingalpha · 6d ago
Akari Therapeutics Q2 2022
Akari Therapeutics (NASDAQ:AKTX) will report on Q2 2022.
Benzinga · 6d ago
-- Earnings Flash (AKTX) AKARI THERAPEUTICS Reports Q2 EPS $0.00
-- Earnings Flash (AKTX) AKARI THERAPEUTICS Reports Q2 EPS $0.00
MT Newswires · 6d ago
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
Benzinga · 09/13 09:14
S&P 500 Rises 1%, InMed Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Monday.
Benzinga · 09/12 18:44
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 09/12 17:57
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
Benzinga · 09/12 16:45
More
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5. Its lead product candidate, Nomacopan, is a recombinant small protein (16,740 Da) that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (membrane attack complex (MAC)), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response. The Company’s pipeline includes two late-stage programs for bullous pemphigoid (BP) and thrombotic microangiopathy (TMA), as well as earlier stage research and development programs in eye and lung diseases with unmet need. Its pre-clinical programs include Nomacopan LA, Votucalis and others.

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.